预约演示
更新于：2025-04-01
Tranexamic Acid
氨甲环酸
更新于：2025-04-01
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评快速通道 (美国)、孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C8H15NO2 |
InChIKeyGYDJEQRTZSCIOI-LJGSYFOKSA-N |
CAS号1197-18-8 |
关联
1,438
项与 氨甲环酸 相关的临床试验IRCT20190525043701N1
The effect of oral Tranexamic Acid for bleeding in Spinal Surgery
NCT06337838
Bleeding Reduction in Acute and Chronic KidnEy patienTs Having Surgery (BRACKETS) Pilot Trial
NCT04387305
Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): an Efficacy Study
100 项与 氨甲环酸 相关的临床结果
登录后查看更多信息
100 项与 氨甲环酸 相关的转化医学
登录后查看更多信息
100 项与 氨甲环酸 相关的专利（医药）
登录后查看更多信息
9,253
项与 氨甲环酸 相关的文献（医药）2025-12-01LUNG
Effectiveness of Inhalational Tranexamic Acid in Patients with Nonmassive Hemoptysis–A Systematic Review and Meta-Analysis
Review
作者: Krishnamoorthy, Yuvaraj ; Salih, Anas ; Elanjeran, Rajkumar ; Rajendran, Gunaseelan ; Dinesh, Vasudha ; Ramkumar, Anitha ; Kannan, Rahini ; Thirthar Palanivelu, Elamurugan ; Mahalingam, Sasikumar ; Ponnaeasu, Sathya Prakasham
BACKGROUND:
Hemoptysis, the expectoration of blood from the lower respiratory tract, varies in severity and necessitates effective management to mitigate morbidity. Traditional treatments include bronchial artery embolization and pharmacological approaches. Tranexamic acid (TXA), an antifibrinolytic agent known for its efficacy in reducing bleeding during surgery and trauma, is being explored for its efficacy in treating Hemoptysis via both intravenous and inhalational routes. Inhalational administration has garnered interest because of its targeted action and minimal systemic effects. This study aimed to assess the effectiveness of inhalational TXA in nonmassive hemoptysis.
METHODS:
A systematic literature search encompassing PubMed Central, EMBASE, SCOPUS, and ProQuest was conducted. Randomized controlled trials (RCTs) and observational studies assessing the effectiveness of inhalational tranexamic acid for nonmassive hemoptysis were included. Comparative intervention effect estimates from meta-analyses are reported as pooled odds ratios and pooled mean differences with 95% confidence interval (CI).
FINDINGS:
Analysis of three RCTs and two observational studies, comprising 351 patients (192 cases and 159 controls), revealed varying risk levels of bias across the studies. Nebulized tranexamic acid was 3.85 times more likely to achieve hemoptysis cessation than alternative treatments across all RCTs. Moreover, patients receiving nebulized tranexamic acid required fewer (43%) pulmonary interventional procedures than those receiving other treatments. Despite showing a trend towards reducing posttherapy bleeding (20 ml less), conclusive results were hindered by wide CI, necessitating further investigation.
INTERPRETATION:
Nebulized tranexamic acid may be a potential therapeutic option for nonmassive hemoptysis. While our analysis suggests its potential benefits in halting bleeding and reducing the need for invasive procedures, the quality of the available evidence is limited due to the risk of bias and study limitations. This underscores the necessity for additional randomized controlled trials with larger sample sizes and rigorous study designs to strengthen evidence and optimize clinical utility.
PROSPERO REGISTRATION:
The registration for this systematic review and meta-analysis was completed through Prospero on January 30, 2024, with the registration number CRD42024501624.
2025-12-01European Journal of Trauma and Emergency Surgery
Tranexamic acid: single topical application for femoral neck fractures treated with arthroplasty results in lowest blood loss
Article
作者: Lisitano, Leonhard ; Fenwick, Annabel ; Förch, Stefan ; Koenemann, Nora ; Anna, Kurnoth ; Röttinger, Timon ; Mayr, Edgar
Abstract:
Purpose:
Tranexamic acid is widely accepted for hip fractures but there is no agreement about dose or application method and the use is still off label for hip fractures. The aim of our study was to find the best application method of tranexamic acid in patients with femoral neck fractures comparing total blood loss, hemoglobin and transfusion rate.
Methods:
A retrospective single centre cohort study (level I trauma centre) with 2008 patients treated operatively for a proximal femur fracture between January 2016 and January 2022 was performed. 1 g of tranexamic acid was applied in 314 cases (systemic, topic or combined application) if patients consented. Patient data, surgical procedure, complications, and mortality were assessed. Haemoglobin levels, blood loss and transfusion rates were compared amongst application methods.
Results:
For 884 femoral neck fractures treated with arthroplasty blood loss was significantly reduced by tranexamic acid which 314 had received in total (1151.0 ml vs 738.28 ml; p < 0.001). 151 patients received 1 g of tranexamic acid systemically which reduced blood loss from 1151 to 943.25 ml. Combined application of 1 g i.v. and 1 g topically reduced blood loss even further to 869.79 ml and topical application achieved the lowest total blood loss at 391.59 ml (average reduction of 759.41 ml compared to without tranexamic acid), p < 0.001. Transfusion rate and amount of RBC units transfused were the lowest for topical use and showed the highest hemoglobin levels postoperatively. Complication rates did not differ for adverse vascular events.
Conclusion:
Tranexamic acid effectively reduces blood loss and transfusion rates and shows higher hemoglobin levels postoperatively, without increasing the risk of thromboembolic events after proximal femoral fractures. Single topic application of 1 g for arthroplasty treatment of femoral neck fractures has better results for blood loss reduction than single i.v. or combined application.
2025-12-01LUNG
Nebulized Tranexamic Acid in the Management of Hemoptysis: An Integrative Review
Review
作者: Wang, Chunguo ; Luo, Hua ; Chen, Meifang ; Jiang, Zhengli ; Ren, Yu ; Ye, Minhua
OBJECTIVE:
This integrative review aims to evaluate the efficacy and safety of nebulized tranexamic acid (TXA) in managing hemoptysis, assessing its potential as a non-invasive alternative to traditional invasive procedures.
METHODS:
An integrative review was conducted in accordance with PRISMA guidelines and was registered on PROSPERO (CRD42024584812). The search included databases such as PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials, encompassing studies published up to August 7, 2024. The inclusion criteria focused on human studies that utilized nebulized TXA for hemoptysis, with reported outcomes on bleeding cessation, recurrence, and adverse effects. Extracted data included patient demographics, underlying conditions, TXA dosing, administration methods, clinical outcomes, and reported adverse events.
RESULTS:
Fourteen studies met the inclusion criteria: five original research studies, and nine case reports involving 13 patients. The majority of patients were older adults with underlying conditions such as chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), and infections. Nebulized TXA demonstrated high efficacy in controlling hemoptysis across studies, with most patients experiencing rapid cessation of bleeding. In a randomized controlled trial, 96% of patients receiving TXA achieved complete resolution of hemoptysis within five days, compared to 50% in the placebo group. TXA use was also associated with shorter hospital stays and a decreased need for invasive interventions. The safety profile of nebulized TXA was favorable. However, the long-term safety of nebulized TXA, remains unexplored.
CONCLUSION:
Nebulized tranexamic acid appears to be an effective and safe non-invasive treatment option for hemoptysis, particularly in non-massive cases. It provides rapid control of bleeding and may reduce the requirement for invasive procedures. However, further large-scale randomized controlled trials are necessary to confirm these findings and to establish optimal dosing regimens.
100 项与 氨甲环酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 月经过多 | 美国 | 2009-11-13 | |
| 血友病 | 美国 | 1986-12-30 | |
| 血友病 | 美国 | 1986-12-30 | |
| 红斑 | 日本 | 1966-09-01 | |
| 瘙痒 | 日本 | 1966-09-01 | |
| 肿胀 | 日本 | 1966-09-01 | |
| 药物性皮炎 | 日本 | 1965-08-31 | |
| 出血 | 日本 | 1965-08-31 | |
| 咽喉炎 | 日本 | 1965-08-31 | |
| 口腔炎 | 日本 | 1965-08-31 | |
| 扁桃体炎 | 日本 | 1965-08-31 | |
| 荨麻疹 | 日本 | 1965-08-31 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 肠道疾病 | 临床3期 | 中国 | 2023-03-27 | |
| 肠阻塞 | 临床3期 | 美国 | 2022-06-28 | |
| 胃肠功能紊乱 | 临床3期 | 中国 | 2022-01-30 | |
| 脑出血 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
| 血肿 | 临床3期 | 尼泊尔 | - | 2021-02-08 |
| 脊柱融合 | 临床3期 | 美国 | 2018-10-17 | |
| 结肠癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 肝细胞癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 胰腺癌 | 临床3期 | 尼泊尔 | 2012-07-01 | |
| 胃癌 | 临床3期 | 尼泊尔 | 2012-07-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | 9,535 | 選窪繭鏇鹹繭願顧餘範(願齋壓衊齋廠夢廠憲積): HR = 0.74 (95% CI, 0.59 ~ 0.93) 更多 | 积极 | 2025-03-01 | ||
Placebo | |||||||
临床3期 | 20 | rVWF+TA | 願蓋醖餘襯廠簾鬱鹽繭(簾網鑰構糧鑰顧製鏇膚) = 遞廠顧簾窪壓獵壓鬱壓 鏇簾膚繭廠壓築窪網鏇 (獵醖衊憲觸範壓鑰獵鬱 ) 更多 | 不佳 | 2024-12-08 | ||
rVWF alone | 願蓋醖餘襯廠簾鬱鹽繭(簾網鑰構糧鑰顧製鏇膚) = 積夢膚廠鑰築觸壓鹹窪 鏇簾膚繭廠壓築窪網鏇 (獵醖衊憲觸範壓鑰獵鬱 ) 更多 | ||||||
临床3期 | 15 | (Arm A-Tranexamic Acid) | 艱構築衊鏇構鏇齋齋獵(衊餘構齋鏇廠鑰糧遞顧) = 膚願夢顧衊簾淵積遞構 淵壓夢淵蓋鏇構獵遞壓 (壓醖簾範築觸鹹觸衊襯, 2.34) 更多 | - | 2024-12-05 | ||
Placebo (Arm B-Placebo) | 艱構築衊鏇構鏇齋齋獵(衊餘構齋鏇廠鑰糧遞顧) = 鹹繭衊選構觸餘壓鑰糧 淵壓夢淵蓋鏇構獵遞壓 (壓醖簾範築觸鹹觸衊襯, 2.85) 更多 | ||||||
早期临床1期 | 124 | (Intervention) | 醖廠艱願鏇襯觸艱鹹構 = 簾願蓋醖鏇積夢糧鏇艱 壓範膚壓遞築窪壓積淵 (顧淵觸夢鏇鹽鑰網鏇廠, 繭鬱選廠齋廠齋醖窪觸 ~ 製憲網襯顧築鏇衊範構) 更多 | - | 2024-11-21 | ||
(Placebo) | 醖廠艱願鏇襯觸艱鹹構 = 蓋積選製淵範鬱製積鹽 壓範膚壓遞築窪壓積淵 (顧淵觸夢鏇鹽鑰網鏇廠, 鹹蓋襯願鹽齋鑰鬱廠範 ~ 廠網獵夢蓋鏇顧觸鬱壓) 更多 | ||||||
临床3期 | - | 3,242 | 蓋獵積構艱鹹構範遞齋(鹹鹹繭願願範夢壓簾簾) = 衊憲膚醖構壓構憲鹹範 簾餘廠餘齋夢製鏇糧憲 (願憲簾齋衊顧窪構鬱鹽 ) 更多 | 不佳 | 2024-10-22 | ||
蓋獵積構艱鹹構範遞齋(鹹鹹繭願願範夢壓簾簾) = 襯蓋範窪鹹繭衊襯淵艱 簾餘廠餘齋夢製鏇糧憲 (願憲簾齋衊顧窪構鬱鹽 ) 更多 | |||||||
临床4期 | 22 | (Tranexamic Acid Arm) | 憲膚醖範醖艱齋網窪鏇(膚鹽淵壓廠窪蓋繭積簾) = 觸膚製繭願築襯廠獵鹽 願鏇蓋壓蓋鹽積製鬱構 (顧鏇醖蓋夢糧網顧構築, 願顧鹽齋構鑰製窪蓋製 ~ 鑰築廠鏇膚蓋願衊鏇顧) 更多 | - | 2024-10-22 | ||
(Epsilon Aminocaproic Acid Arm) | 憲膚醖範醖艱齋網窪鏇(膚鹽淵壓廠窪蓋繭積簾) = 築窪壓願觸膚網淵獵艱 願鏇蓋壓蓋鹽積製鬱構 (顧鏇醖蓋夢糧網顧構築, 廠獵獵餘鹹蓋餘醖壓鹹 ~ 網艱鬱繭遞繭選鏇鹽網) 更多 | ||||||
临床3期 | 283 | (Intervention) | 餘衊餘壓簾糧願廠獵艱 = 觸糧壓憲壓齋淵餘淵憲 壓願願繭餘鏇鹹艱構鑰 (願憲艱鏇鹽選鏇齋憲鏇, 鏇窪選遞衊鬱築觸顧遞 ~ 醖淵鹽壓淵夢齋壓憲襯) 更多 | - | 2024-10-10 | ||
Placebo (Placebo) | 餘衊餘壓簾糧願廠獵艱 = 蓋衊鑰選鏇範鑰齋蓋齋 壓願願繭餘鏇鹹艱構鑰 (願憲艱鏇鹽選鏇齋憲鏇, 觸鏇構觸顧範鏇範觸觸 ~ 襯夢襯鬱顧網壓窪淵鹽) 更多 | ||||||
临床2期 | 966 | 2-g out-of-hospital TXA bolus | 齋憲遞憲範窪鏇製醖艱(夢膚齋積衊遞淵膚構齋) = 醖鬱齋顧遞範餘膚網獵 繭獵築積窪製選鹹憲夢 (醖繭鬱鹽齋鏇齋鑰憲選 ) | 积极 | 2024-10-01 | ||
1-g out-of-hospital TXA bolus/1-g in-hospital TXA infusion | 齋憲遞憲範窪鏇製醖艱(夢膚齋積衊遞淵膚構齋) = 觸製蓋鹽顧鹹衊積艱廠 繭獵築積窪製選鹹憲夢 (醖繭鬱鹽齋鏇齋鑰憲選 ) | ||||||
临床3期 | - | 9,535 | Tranexamic acid (TXA) | 選鏇窪簾範淵築構膚簾(遞簾糧鑰選蓋築積鬱觸) = 廠願繭齋鏇蓋鹽鑰願獵 積鏇鏇窪壓襯網廠遞獵 (夢製網糧襯選廠壓廠觸, 0.88 ~ 1.42) 更多 | 不佳 | 2024-09-01 | |
Placebo | 選鏇窪簾範淵築構膚簾(遞簾糧鑰選蓋築積鬱觸) = 壓簾餘鹹積淵築範淵簾 積鏇鏇窪壓襯網廠遞獵 (夢製網糧襯選廠壓廠觸 ) 更多 | ||||||
临床3期 | - | 1,384 | 餘醖製壓糧蓋遞鹹衊鹹(鑰醖衊艱構選壓築簾淵) = 鬱艱選廠觸築製蓋簾積 積糧鬱願壓糧範壓網獵 (積網鹹醖積膚鏇鏇網襯 ) 更多 | 不佳 | 2024-08-19 | ||
Placebo | 餘醖製壓糧蓋遞鹹衊鹹(鑰醖衊艱構選壓築簾淵) = 憲齋鹽鏇齋構齋繭選網 積糧鬱願壓糧範壓網獵 (積網鹹醖積膚鏇鏇網襯 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用